At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 425 enrolled
Drug / intervention
Nivolumab +2 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Double-Blind, Randomized, Two Arm Phase 2 Study of Nivolumab in Combination With Ipilimumab Versus Nivolumab in Combination With Ipilimumab Placebo in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)
In Brief
A Phase 2 clinical trial evaluating Nivolumab, Ipilimumab, and 1 other intervention for Head and Neck Cancer. Completed, enrolled 425 participants across 105 sites in 21 countries.
Detailed Summary
A study in patients with metastatic or recurrent squamous cell cancer of the head and neck to evaluate the effectiveness of Nivolumab plus Ipilumumab vs. Nivolumab alone (CheckMate 714)
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHead and Neck Cancer
CountriesArgentina, Belgium, Brazil, Canada, Chile, Czechia, Finland, France, Ireland, Italy, Mexico, Netherlands, Norway, Romania, Russia, South Africa, Spain, Sweden, Turkey (Türkiye), United Kingdom, United States
Collaborators--
Timeline
Phase 2CompletedFinished
2017201820192020202120222023202420252026
First PostedJul 2016
Enrollment StartNov 2016
Primary CompletionJan 2019
Study CompletionApr 2022
TodayJul 2026
First PostedJul 6, 2016
Enrollment StartNov 8, 2016
Primary CompletionJan 23, 2019
Study CompletionApr 21, 2022
TodayJul 2, 2026
Enrollment to primary: 2.2 yearsPosted 10.0 years ago
Interventions
Nivolumabbiological
Ipilimumabbiological
Placeboother